{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:30:53Z","timestamp":1792225853867,"version":"4.4.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4-5","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathologie Biologie"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.patbio.2015.06.002","type":"journal-article","created":{"date-parts":[[2015,8,17]],"date-time":"2015-08-17T14:26:04Z","timestamp":1439821564000},"page":"210-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0820-692X","authenticated-orcid":false,"given":"R.","family":"Djidjik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Lounici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Chergeula\u00efne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Berkouk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mouhoub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Chaib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Belhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ghaffor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.patbio.2015.06.002_bib0155","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1056\/NEJMra041875","article-title":"Multiple myeloma","volume":"351","author":"Kyle","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.patbio.2015.06.002_bib0160","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.4065\/80.10.1371","article-title":"Multiple myeloma: diagnosis and treatment","volume":"80","author":"Rajkumar","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.patbio.2015.06.002_bib0165","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1200\/JCO.1994.12.11.2398","article-title":"Immunoglobulin D multiple myeloma presenting features response to therapy, and survival in a series of 53 cases","volume":"12","author":"Blad\u00e9","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0170","first-page":"1018","article-title":"Deux cas de myelome avec immunoglobuline IgD a character monoclonal","volume":"14","author":"Fine","year":"1969","journal-title":"Rev Fr Etudes Clin Biol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0175","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0002-9343(68)90071-5","article-title":"Plasma cell myeloma with D-myeloma protein (IgD myeloma)","volume":"45","author":"Fahey","year":"1968","journal-title":"Am J Med"},{"key":"10.1016\/j.patbio.2015.06.002_bib0180","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1001\/archinte.1975.00330010089012","article-title":"IgD multiple myeloma. Review of 133 cases","volume":"135","author":"Jancelewicz","year":"1975","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.patbio.2015.06.002_bib0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1182\/blood-2011-06-358895","article-title":"Immunoglobulin D amyloidosis: a distinct entity","volume":"119","author":"Gertz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.patbio.2015.06.002_bib0190","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/clinchem\/47.4.673","article-title":"Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine","volume":"47","author":"Bradwell","year":"2001","journal-title":"Clin Chem"},{"key":"10.1016\/j.patbio.2015.06.002_bib0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1529-1049(02)00064-8","article-title":"Serum free light chain immunoassays and their clinical application","volume":"3","author":"Bradwell","year":"2002","journal-title":"Clin Appl Immunol Rev"},{"issue":"2","key":"10.1016\/j.patbio.2015.06.002_bib0200","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/leu.2008.307","article-title":"International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders","volume":"23","author":"Dispenzieri","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.patbio.2015.06.002_bib0205","doi-asserted-by":"crossref","first-page":"106","DOI":"10.5858\/1999-123-0106-GFCALE","article-title":"Guidelines for clinical and laboratory evaluation patients with monoclonal gammopathies","volume":"123","author":"Keren","year":"1999","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.patbio.2015.06.002_bib0210","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/clinchem\/48.9.1437","article-title":"Serum reference intervals and diagnostic ranges for free kappa and free lambda immunogloblin light chains","volume":"48","author":"Katzmann","year":"2002","journal-title":"Clin Chem"},{"key":"10.1016\/j.patbio.2015.06.002_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/1471-2369-9-11","article-title":"Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure","volume":"9","author":"Hutchison","year":"2008","journal-title":"BMC Nephrol"},{"issue":"10","key":"10.1016\/j.patbio.2015.06.002_bib0220","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1038\/leu.2008.171","article-title":"Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system","volume":"22","author":"Snozek","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.patbio.2015.06.002_bib0225","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/1097-0142(197509)36:3<842::AID-CNCR2820360303>3.0.CO;2-U","article-title":"A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features response to treatment, and survival","volume":"36","author":"Durie","year":"1975","journal-title":"Cancer"},{"key":"10.1016\/j.patbio.2015.06.002_bib0310","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1756-9966-31-17","article-title":"IgD multiple myeloma a descriptive report of 17\u00a0cases: survival and response to therapy","volume":"31","author":"Pisani","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.patbio.2015.06.002_bib0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00277-004-0944-x","article-title":"IgD multiple myeloma\u2013a clinical profile and outcome with chemotherapy and autologous stem cell transplantation","volume":"84","author":"Wechalekar","year":"2005","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.patbio.2015.06.002_bib0240","first-page":"161","article-title":"IgD myeloma associated with multiple extramedullary amyloid containing tumors and amyloid casts in the renal tubules","volume":"2","author":"Friman","year":"1970","journal-title":"Ann Clin Res"},{"key":"10.1016\/j.patbio.2015.06.002_bib0245","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1600-0609.1991.tb01569.x","article-title":"A new risk grouping for IgD myeloma based on analysis of 165 Japanese patients","volume":"47","author":"Shimamoto","year":"1991","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0250","first-page":"1061","article-title":"IgD plasma cell neoplasia: clinical manifestations and characteristic features","volume":"102","author":"Pruzanski","year":"1970","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.patbio.2015.06.002_bib0255","first-page":"1110","article-title":"Immunoglobulin D multiple myeloma. A retrospective study in the Languedoc region","volume":"18","author":"LeQuellec","year":"1989","journal-title":"Presse Med"},{"issue":"5","key":"10.1016\/j.patbio.2015.06.002_bib0260","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1600-0609.1984.tb00727.x","article-title":"Prognostic factors in IgD myeloma: a study of 21 cases","volume":"33","author":"Fibbe","year":"1984","journal-title":"Scand J Haematol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0265","first-page":"1227","article-title":"Le my\u00e9lome \u00e0 IgD, \u00e0 propos d\u2019un cas","volume":"51","author":"Alcalay","year":"1975","journal-title":"Sem Hop"},{"issue":"7","key":"10.1016\/j.patbio.2015.06.002_bib0270","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/00268970500096442","article-title":"Immunoglobulin D myeloma\u2013Problems with diagnosing and staging (own experience and literature review)","volume":"46","author":"Kuliszkiewicz-Janus","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.patbio.2015.06.002_bib0275","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","article-title":"International staging system for multiple myeloma","volume":"23","author":"Greipp","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0280","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00277-004-0944-x","article-title":"IgD multiple myeloma\u2013a clinical profile and outcome with chemotherapy and autologous stem cell transplantation","volume":"84","author":"Wechalekar","year":"2005","journal-title":"Ann Hematol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0285","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1365-2141.2007.06561.x","article-title":"Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma","volume":"137","author":"Kyrtsonis","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0290","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/j.1365-2141.2004.05045.x","article-title":"Serum free light chains for monitoring multiple myeloma","volume":"126","author":"Mead","year":"2004","journal-title":"Br J Haematol"},{"key":"10.1016\/j.patbio.2015.06.002_bib0295","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0140-6736(03)12457-9","article-title":"Serum test for assessment of patients with Bence Jones myeloma","volume":"361","author":"Bradwell","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.patbio.2015.06.002_bib0300","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1182\/blood-2007-01-067728","article-title":"High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis","volume":"110","author":"van Rhee","year":"2007","journal-title":"Blood"}],"container-title":["Pathologie Biologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811415000577?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0369811415000577?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T14:37:55Z","timestamp":1653057475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0369811415000577"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":30,"journal-issue":{"issue":"4-5","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S0369811415000577"],"URL":"https:\/\/doi.org\/10.1016\/j.patbio.2015.06.002","relation":{},"ISSN":["0369-8114"],"issn-type":[{"value":"0369-8114","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay","name":"articletitle","label":"Article Title"},{"value":"Pathologie Biologie","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.patbio.2015.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}